Lenacapavir, a novel HIV treatment and prevention tool approved by the United States Food and Drug Administration (FDA) represents a significant advancement in the fight against HIV. Administered as a twice-yearly injection, it offers a convenient and effective option for managing HIV. However, the high cost associated with Lenacapavir primarily due to the patent held by Gilead Sciences until 2037 poses a major barrier to its access particularly in low- and middle-income countries (LMICs) such as Kenya.
According to the Medicines Patent Pool database, Gilead’s patent on Lenacapavir restricts the production of more affordable generic versions leading to exorbitant prices. The annual cost for the two injections can reach up to KES 5.7 million, making it inaccessible to most individuals who need it most.
KELIN advocates for health-related human-rights for all and stands in solidarity with the global movement advocating for equitable access to essential medicines. It is crucial that Lenacapavir which is a life-saving medication, be made available at an affordable price to LMICs including Kenya. The current patent restrictions hinder our ability to combat HIV effectively and ensure that those living with HIV can lead healthier lives.
We urge Gilead Sciences and other stakeholders to prioritize public health over profits and take immediate steps to facilitate the availability of Lenacapavir in LMICs. This includes considering voluntary licensing agreements, reducing the cost of the drug, and working with international health organizations to ensure its widespread distribution.
